Tocilizumab: Efficacy and Tolerance in Rheumatoid Arthritis in Current Practice
PDF

Keywords

Rheumatoid arthritis
Tocilizumab
Efficacy
Tolerance

How to Cite

1.
Akasbi N, Mounir A, Omboumahou Bakale FE, El Fakir S, Harzy T. Tocilizumab: Efficacy and Tolerance in Rheumatoid Arthritis in Current Practice. Integr J Med Sci [Internet]. 2019Apr.26 [cited 2020Sep.27];6. Available from: http://mbmj.org/index.php/ijms/article/view/96

Abstract

Introduction: The aim of this study was to evaluate in “real life” the efficacy and the tolerance of Tocilizumab (TCZ) in the treatment of rhumatoide arthritis (RA).
Materials and methods: A cross-sectional study including patients with RA patients treated with TCZ at the commended dose of 8 mg/kg/ 4 weeks. The therapeutic response was evaluated by the EULAR DAS 28 ‐CRP/ VS at month 3 and month 6 of treatment.
Results: RA was in most cases severe (76,5 %), seropositive (88,2 %) and erosive (81,3 %). TCZ was prescribed as an alternative to a previous biotherapy in 23 % of the patients and in monotherapy in 76, 5 % of the patients. After treatment follow-up at 3 and 6 months, the different parameters observed were significantly improved including: VAS (visual analogue scale) pain (p=0,000), CRP (mg/L) p=0,000), ESR (mmH1) (p=0,000), DAS 28 CRP (p=0,000), and DAS 28 ESR (p=0,000). Apart from a worsening of renal function in a patient contraindicated continuation of tocilizumab, no serious side effects were noted.
Conclusion: Our study confirmed the efficacy and tolerance of TCZ therapy in Moroccan patients suffering from RA.
Key words: rheumatoid arthritis, tocilizumab, efficacy, tolerance

https://doi.org/10.15342/ijms.v6ir.253
PDF
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2019 Nessrine Akasbi et al.